| Document |
Document Title |
|
JP5784295B2 |
|
|
JP5781930B2 |
The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directe...
|
|
JP5763203B2 |
The present invention discloses a method for producing antihypertensive active peptides with corn germ protein as the material. The method comprises an alkali-heat treatment and continuous enzymolysis of the corn germ protein. The compon...
|
|
JP5747374B2 |
|
|
JP5745229B2 |
|
|
JP5695326B2 |
A protein synthesis promoter that exhibits a protein synthesis-promoting effect includes a whey protein hydrolyzate having a molecular weight distribution that is within a range of 10 kDa or less and has a main peak of 200 Da to 3 kDa, a...
|
|
JP2015057074A |
To provide modified isoprenoid synthases.Provided is a chimeric isoprenoid synthase polypeptide comprising a first domain derived from a first isoprenoid synthase, the first domain being joined to a second domain derived from a second he...
|
|
JP5676538B2 |
A polypeptide, a nucleic acid molecule encoding the polypeptide and a pharmaceutical composition comprising an effective amount of the polypeptide are provided. The polypeptide is as defined in the description, can bind to insulin recept...
|
|
JP5677454B2 |
An intracellular targeting bipodal-peptide binder specifically binding to an intracellular target molecule, comprising: (a) a structure-stabilizing region comprising a parallel amino acid strand, an antiparallel amino acid strand or para...
|
|
JP5667207B2 |
The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins compris...
|
|
JP5642126B2 |
To provide a material for forming a self-organization pattern that can make a nanometer order fine pattern in which etching resistance is high.Provided is a compound in which a silsesquioxane skeleton having a group selected from a group...
|
|
JP2014221062A |
To provide compositions and methods for detection of polynucleotides and polypeptides of Anaplasma platys that causes a cyclic thrombocytopenia in a dog.The invention provides: a method for detecting polypeptides using an antibody that s...
|
|
JP5620282B2 |
The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.
|
|
JP5525749B2 |
Inter alia , there are disclosed linear random amino acid copolymers characterized by substantially comprising amino acids tyrosine (Y), phenyalanine (F), alanine (A) and lysine (K).
|
|
JP2014050386A |
To provide methods of diagnosing, treating and preventing celiac disease comprising administering to an individual a therapeutic composition comprising at least one epitope.Methods of preventing or treating celiac disease comprise admini...
|
|
JP2014502152A |
Compositions and methods for increasing p53-dependent transcriptional activity in a cell.
|
|
JP5390621B2 |
The present invention deals with a bipodal-peptide binder that specifically binds with a target including (a) a structure stabilizing region that includes parallel, antiparallel or parallel and antiparallel amino acid strands wherein int...
|
|
JP2013544798A |
The invention provides methods and compositions for modulating the Wnt signaling pathway, in particular by interfering with binding of Dkk1 or SOST with LRP5 and/or LRP6.
|
|
JP5329381B2 |
The present invention relates to chromatography ligands having improved caustic stability, e.g., ligands based on immunoglobulin-binding proteins such as, Staphylococcal protein A, as well as methods of making and using such ligands.
|
|
JP2013216585A |
To provide an uranium adsorptive peptide capable of adsorbing uranyl ion specifically in the front layer of a microorganism.An uranium adsorptive peptide includes a dimer of C-terminal-domain mutants of a nickel ion-dependent transfer in...
|
|
JP5278873B2 |
To provide a cancer diagnosing reagent capable of judging whether cancer is present or recognizing the progress degree or expanse of cancer by simple operation for measuring activity by bringing the body fluid such as urine or plasma of ...
|
|
JP2013144691A |
To provide a ready-to-use liquid formulation of botulinum toxin that can be conveniently shipped, stored and used as needed.A composition is for treating a patient in need of inhibition of cholinergic transmission to selected muscle or m...
|
|
JP2013525271A |
The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune re...
|
|
JP2013522300A |
The present invention encompasses BTV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing BTV antigens. The invention also encompasses recombinant vectors encoding and expressing BTV antigens, ...
|
|
JP2013520419A |
The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets...
|
|
JP2013510297A |
The invention provides methods for detecting the presence of an aggregate in a sample by contacting the sample suspected of containing an aggregate with an aggregate-specific binding reagent under conditions that allow the binding of the...
|
|
JP5152831B2 |
|
|
JP2013505944A |
Ligand Drug Conjugates are provided having a DR5 binding moiety attached via linking groups and/or spacers to a therapeutic agent and are effective in treatment of various cancers.
|
|
JP5149269B2 |
Specific peptides have been discovered that mimic an idiotype of an autoantibody. Such peptides may be formed into polymers. The peptides may be used in pharmaceutical compositions for the treatment of an autoimmune disease together with...
|
|
JP5117648B2 |
The present invention provides cationic-polymer-lipid conjugates (CPLs) such as distal cationic-poly(ethylene glycol)-lipid conjugates which can be incorporated into conventional and stealth liposomes or other lipid-based formulation for...
|
|
JP5073912B2 |
This invention is directed to prodrugs that can be activated at the preferred site of action in order to selectively deliver the corresponding therapeutic parent drugs to target cells or to the target site. This invention will therefore ...
|
|
JP5032458B2 |
The present invention relates to novel rodent control agents comprising antibodies, or antigen-binding fragments thereof, that bind to proteins expressed in rodents and in particular antibodies or antigen-binding fragments that bind to p...
|
|
JP5037122B2 |
Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic proc...
|
|
JP5014148B2 |
It is an object of the present invention to provide a novel method for producing a peptide thioester. In the present invention, general peptide synthesis is performed on a solid-phase resin, carboxylic acid obtained after cutout is allow...
|
|
JP5015409B2 |
The present invention relates to improved chelator conjugates with biological targeting molecules, suitable for forming metal complexes with radiometals. The radiometal complexes, especially with the radiometal 99mTc, are useful as radio...
|
|
JP4993463B2 |
The invention relates to new peptide-based compounds and their use in diagnostic optical imaging. More specifically the invention relates to the use of such peptide-based compounds as targeting vectors that bind to receptors associated w...
|
|
JP4991897B2 |
A method of enzymatically producing a protein hydrolysate from a protein substrate is described, wherein a proline-specific endoprotease or a composition containing a proline-specific endoprotease and optionally a subtilisin or a metallo...
|
|
JP2012140444A |
To provide 3-aminocaprolactam derivatives for preparation of a medicament intended to treat an inflammatory disorder.There are provided the compounds represented by general formula (I) (wherein X is -CO-Y-(R1)n or SO2-Y-(R1)n; and Y is c...
|
|
JP4971149B2 |
The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which ...
|
|
JP2012122075A |
To provide a method of increasing intracellular delivery of nucleic acid, and to provide an artificial virus that has high transfection titer and transfection efficiency.For enhancing cellular uptake, cationic polymer-lipid conjugates (C...
|
|
JP4947475B2 |
Avian cartilage hydrolyzate comprises hydrolyzed type II collagen (45-70 wt.%), chondroitin sulfate (9-15 wt.%), hyaluronic acid (0.5-2 wt.%) and amino acids such as valine (2.7-3.3%), isoleucine (2-2.4%), phenylalanine (2.2-2.6%), lysin...
|
|
JP2012505645A |
It contains at least 300 mg / l of hydrophobin and at least 0.3 mg / l of defoaming agent, and the weight ratio of defoaming agent / hydrofoaming is less than 0.2, preferably less than 0.15, more preferably less than 0.1. Aqueous solution.
|
|
JP2012504619A |
The invention provides inhibitors of ghrelin O-acyltransferase, and methods of making and using them. In some embodiments, the invention provides bisubstrate analog inhibitors of ghrelin O-acyltransferase, which can be effective in treat...
|
|
JP2012502664A |
The present invention relates to methods of growing and maintaining pluripotent cells on an insoluble substrate that presents a peptide that binds to glycosaminoglycans, such as heparin. Specifically, methods of growing and maintaining p...
|
|
JP2012005499A |
To provide a modified isoprenoid synthase.There are provided: a chimeric isoprenoid synthase polypeptide including a first domain from a first isoprenoid synthase joined to a second domain from a second heterologous isoprenoid synthase, ...
|
|
JP4799820B2 |
Disclosed are peptide agents and uses thereof that are analogs of biologically active peptides such as somatostatin and bombesin. The compounds of the invention have the general formula X-Y-Z-Q, where X is a cytotoxic agent, therapeutic ...
|
|
JP2011172596A |
To provide a therapeutic oligomer-peptide conjugate, and methods of using the conjugate.The therapeutic oligomer-peptide conjugate includes (a) a substantially uncharged oligonucleotide analog compound having a base sequence that include...
|
|
JP4741471B2 |
A process for isolating low molecular weight ("LMW") peptides from tissue in situ comprising the steps: a) homogenizing the tissue; b) mixing the homogenized tissue with an organic solvent to form a fully-wetted slurry; c) standing or ag...
|
|
JP4732585B2 |
The invention discloses the Moraxella catarrhalis outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Al...
|
|
JP4686792B1 |
To provide angiotensin I converting enzyme from wheat bran, barley bran and rice bran without adding protease or amylase and without adding a substance harmful to the human body, economically and efficiently. It is an object of the prese...
|
